A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? In this feature, Ben Hargreaves looks at all of the factors involved and how the increased return can be maintained.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,